var data={"title":"Tranexamic acid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tranexamic acid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7083?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">see &quot;Tranexamic acid: Drug information&quot;</a> and <a href=\"topic.htm?path=tranexamic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tranexamic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229860\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cyklokapron;</li>\n      <li>Lysteda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229861\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cyklokapron;</li>\n      <li>GD-Tranexamic Acid;</li>\n      <li>Tranexamic Acid Injection;</li>\n      <li>Tranexamic Acid Injection BP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062679\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifibrinolytic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hemostatic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675770\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of bleeding associated with ECMO during surgery for congenital diaphragmatic hernia repair:</b> Limited data available: Term neonates: IV: Loading dose: 4 mg/kg as a single dose 30 to 60 minutes before repair, followed by a continuous infusion of 1 mg/kg/<b>hour</b> for 24 hours, was reported to reduce blood loss and hemorrhagic complications (Keijzer, 2012; van der Staak, 1997) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of perioperative bleeding associated with cardiac surgery:</b> Limited data available; reported dosing regimens variable and ideal dose-response not established: Term neonates (GA &gt;36 weeks at time of procedure):  IV: Loading dose: 100 mg/kg over 15 minutes, priming dose: 100 mg/kg into the by-pass circuit followed by and infusion at 10 mg/kg/hour (Graham, 2012; Schindler, 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062673\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">see &quot;Tranexamic acid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Menorrhagia:</b> Female Children &ge;12 years and Adolescents:  Oral: Tablet: 1,300 mg 3 times daily; maximum daily dose: 3900 mg/<b>day</b> for up to 5 days during monthly menstruation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of bleeding associated with tooth extraction in hemophilic patients (in combination with replacement therapy):</b> Infants, Children, and Adolescents: IV: 10 mg/kg immediately before surgery, then 10 mg/kg/dose 3 to 4 times daily; may be used for 2 to 8 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of bleeding associated with cardiac surgery:</b> Limited data available; reported regimens variable and ideal dose-response not established: Infants, Children, and Adolescents &le;15 years: IV: 10 mg/kg into the by-pass circuit after induction, during cardiopulmonary bypass, and after protamine reversal of heparin for a total of 3 doses; regimen used in two separate trials (n=80, age range: 2 months to 15 years) (Chauhan, 2004; Chauhan, 2004a). Also reported in the younger patients undergoing cardiac surgery (typically &lt;2 years or 20 kg): Loading dose: 100 mg/kg, followed by 10 mg/kg/hour IV infusion (continued until ICU transport) and 100 mg/kg priming dose into the circuit when by-pass initiated (Reid, 1997; Schindler, 2011). In children 1 to 12 years and weighing 5 to 40 kg, a pharmacokinetic analysis proposed the following regimen to achieve a target serum concentration range of 20 to 30 mcg/mL: IV: Loading dose: 6.4 mg/kg over 5 minutes followed by a weight-adjusted continuous infusion in the range of 2 to 3.1 mg/kg/hour; the pharmacokinetic data showed that patients weighing less should receive an initial infusion rate at the higher end of the range (ie, if patient weight =5 kg then initial infusion rate: 3.1 mg/kg/hour; or if patient weight =40 kg then initial infusion rate: 2 mg/kg/hour) (Grassin-Deyle, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of perioperative bleeding associated with spinal surgery (eg, idiopathic scoliosis):</b> Limited data available; reported dosing regimens variable; ideal dose response not established: Children &ge;8 years and Adolescents: IV: Loading dose: 100 mg/kg, followed by infusion at 10 mg/kg/hour until skin closure (Sethna, 2005; Shapiro 2007). Other reported regimens with positive results: Loading dose: 20 mg/kg, followed by 10 mg/kg/hour infusion (Grant, 2009) or loading dose: 10 mg/kg and 1 mg/kg/hour infusion (Grant, 2009; Neilipovitz, 2001) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of perioperative bleeding associated with craniosyntosis surgery:</b> Limited data available; reported dosing regimens variable; ideal dose-response not established: Infants &ge;2 months and Children &le;6 years: IV: Loading dose of 50 mg/kg over 15 minutes prior to incision, followed by infusion at 5 mg/kg/hour until skin closure (Goobie, 2011) <b>or</b> 15 mg/kg over 15 minutes prior to incision, followed by infusion at 10 mg/kg/hour until skin closure (Dadure, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (HAE), prophylaxis:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Long-term prophylaxis: Oral: 20 to 75 mg/kg/day in 2 to 3 divided doses; maximum daily dose range: 3,000 to 6,000 mg/<b>day</b> (Bowen, 2010; Farkas, 2007; Gompels, 2005; Zuraw, 2013) <b>or</b> 1,000 to 2,000 mg daily (~50 mg/kg/day; depending on age and size of patient); may consider alternate-day regimen or twice-weekly regimen when frequency of attacks reduces; diarrhea may be a dose-limiting side effect (Gompels, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Short-term prophylaxis (eg, prior to surgical or diagnostic interventions in head/neck region): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed: 20 to 40 mg/kg/day in 2 to 3 divided doses; maximum daily dose: 6,000 mg/<b>day</b> (Bowen, 2010; Farkas, 2007); other guidelines suggest 50 to 75 mg/kg/day in 2 to 3 divided doses (Craig [WAO], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed dosing: Patients with an adequate weight (eg, &ge;50 kg): 500 mg 4 times daily (Gompels, 2005); therapy usually initiated 2 to 5 days before dental work and continue for 2 days after the procedure (Bowen, 2004; Gompels, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Traumatic hyphema:</b> Limited data available: Children and Adolescents: Oral: 25 mg/kg/dose every 8 hours for 5 to 7 days (Rahmani, 1999; Vangsted, 1983). <b>Note:</b> This same regimen may also be used for secondary hemorrhage after an initial traumatic hyphema event.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tooth extraction in patients with hemophilia (in combination with replacement therapy):</b> IV: 10 mg/kg immediately before surgery, then 10 mg/kg/dose 3 to 4 times daily; may be used for 2 to 8 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Menorrhagia:</b> Oral: 1300 mg 3 times daily (3,900 mg/day) for up to 5 days during monthly menstruation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> <b>Note:</b> Recommendations are dependent on use and route. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: <b>Menorrhagia:</b> Female Children &ge;12 years, Adolescents, and Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> &gt;1.4 to 2.8 mg/dL: 1,300 mg twice daily (2,600 mg/day) for up to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> 2.9 to 5.7 mg/dL: 1,300 mg once daily for up to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> &gt;5.7 mg/dL: 650 mg once daily for up to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Tooth extraction in patients with hemophilia:</b> Infants, Children, Adolescents, and Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> 1.36 to 2.83 mg/dL: Maintenance dose of 10 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> &gt;2.83 to 5.66 mg/dL: Maintenance dose of 10 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> &gt;5.66 mg/dL: Maintenance dose of 10 mg/kg/dose every 48 hours <b>or</b> 5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: No adjustment is necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229847\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyklokapron: 1000 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lysteda: 650 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 650 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229834\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062683\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer without regard to meals; tablets should be swallowed whole; do not break, split, chew, or crush.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV doses: May be administered undiluted (100 mg/mL) by direct IV injection; use plastic syringe only for IV push; or may further dilute dose and infuse over 5 to 30 minutes; maximum administration rate: 100 mg/minute </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous IV infusion: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Loading doses: In perioperative pediatric trials, loading doses were administered either undiluted or diluted and infused over 15 minutes (Dadure 2011; Goobie 2011; Neilipovitz 2001; Reid 1997; Sethna 2005). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV infusion: After dilution, administer by continuous IV infusion at a rate not to exceed 100 mg/minute. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adult: Loading doses: Usually diluted and administered over 5 to 30 minutes. Maximum administration rate: 100 mg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7679527\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Diluted mixture may be stored for up to 4 hours at room temperature. However, solutions prepared in NS are chemically stable for up to 180 days at room temperature (McCluskey 2014). In another study, tranexamic acid (undiluted) was shown to be chemically stable for up to 12 weeks when stored at -20&deg;C, 4&deg;C, 22&deg;C, and 50&deg;C; freezing tranexamic acid in original ampules is unacceptable due to cracking of the ampules (de Guzman 2013). Freezing tranexamic acid in original vials has not been evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062682\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Tablet (Lysteda): Treatment of cyclic heavy menstrual bleeding (menorrhagia) (FDA approved in females &ge;12 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Short-term use (2 to 8 days) in hemophilia patients to reduce or prevent hemorrhage and reduce need for blood factor replacement therapy during and following tooth extraction (FDA approved in pediatric patients [age not specified] and adults); has also been used to decrease perioperative blood loss and the need for transfusion in patients undergoing congenital heart disease corrective surgery, scoliosis-related surgery, craniosynostosis surgery and congenital diaphragmatic hernia repair with ECMO; orally administered for the prevention of hereditary angioedema attacks (HAE) (long and short-term) and for management of traumatic hyphema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229906\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cyklokapron may be confused with cycloSPORINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">TXA (occasional abbreviation for tranexamic acid) is an error-prone abbreviation (mistaken as TNK an error-prone abbreviation for tenecteplase)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229904\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue (oral), headache (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain (oral)</p>\n    <p style=\"text-indent:-6em;margin-left:6em;\">Hematologic &amp; oncologic: Anemia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (oral), back pain (oral), muscle cramps (oral), muscle spasm (oral), musculoskeletal pain (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal signs and symptoms (oral; including sinus symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Allergic dermatitis, allergic skin reaction, anaphylactic shock, anaphylactoid reaction, anaphylaxis, cerebral thrombosis, chromatopsia, conjunctivitis (ligneous), deep vein thrombosis, diarrhea, dizziness, hypersensitivity reaction, hypotension (with rapid IV injection), nausea, pulmonary embolism, renal cortical necrosis, retinal artery occlusion, retinal vein occlusion, seizure, ureteral obstruction, visual disturbance, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229853\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Hypersensitivity to tranexamic acid or any component of the formulation; acquired defective color vision; active intravascular clotting; subarachnoid hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Hypersensitivity to tranexamic acid or any component of the formulation; active thromboembolic disease (eg, cerebral thrombosis, DVT, or PE); history of thrombosis or thromboembolism, including retinal vein or retinal artery occlusion; intrinsic risk of thrombosis or thromboembolism (eg, hypercoagulopathy, thrombogenic cardiac rhythm disease, thrombogenic valvular disease); concurrent use of combination hormonal contraception</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Injection, oral: Hypersensitivity to tranexamic acid or any component of the formulation; acquired defective color vision; history or risk of thrombosis (unless concurrent anticoagulation therapy is possible); active thromboembolic disease (eg, deep vein thrombosis, pulmonary embolism, cerebral thrombosis); subarachnoid hemorrhage; hematuria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229838\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis or anaphylactoid reaction have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Visual defects (eg, color vision change, visual loss) and retinal venous and arterial occlusions have been reported; discontinue treatment if ocular changes occur; prompt ophthalmic examination should be performed by an ophthalmologist. Use of the injection is contraindicated in patients with acquired defective color vision. Ligneous conjunctivitis has been reported with the oral formulation, but resolved upon discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure: Seizures have been reported with use; most often with intraoperative use (eg, open chamber cardiac surgery) and in older patients (Murkin 2010). The mechanism by which tranexamic acid use results in seizures may be secondary to neuronal gamma aminobutyric acid (GABA) inhibition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Venous and arterial thrombosis or thromboembolism, including central retinal artery/vein obstruction, has been reported. Use the injection with caution in patients with thromboembolic disease; oral formulation is contraindicated in patients with a history of or active thromboembolic disease or with an intrinsic risk of thromboembolic events (eg, thrombogenic valvular disease, thrombogenic cardiac rhythm disease, hypercoagulopathy). Concomitant use with certain procoagulant agents (eg, anti-inhibitor coagulant complex/factor IX complex concentrates, oral tretinoin, hormonal contraceptives) may further increase the risk of thrombosis; concurrent use with either the oral or injectable formulation may be contraindicated, not recommended, or to be used with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ureteral obstruction: Use the injection with caution in patients with upper urinary tract bleeding, ureteral obstruction due to clot formation has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disseminated intravascular coagulation (DIC): Use with extreme caution in patients with DIC requiring antifibrinolytic therapy; patients should be under strict supervision of a health care provider experienced in treating this disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Subarachnoid hemorrhage: Use oral formulation with caution in patients with subarachnoid hemorrhage; cerebral edema and infarction may occur. Use of the injection is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vascular disease: Use with caution in patients with uncorrected cardiovascular or cerebrovascular disease due to the complications of thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300160\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229842\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12854&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anti-inhibitor Coagulant Complex (Human): Antifibrinolytic Agents may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): May enhance the thrombogenic effect of Tranexamic Acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): May enhance the thrombogenic effect of Tranexamic Acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tretinoin (Systemic): May enhance the thrombogenic effect of Antifibrinolytic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229843\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7679524\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Tranexamic acid crosses the placenta and concentrations within cord blood are similar to maternal concentrations. Tranexamic acid has been evaluated for the treatment of postpartum hemorrhage (Ducloy-Bouthors 2011; Gungorduk 2011; WOMAN Trial Collaborators 2017). A significant reduction in risk of death due to bleeding was observed when treatment was started within 3 hours of vaginal birth or cesarean section (WOMAN Trial Collaborators 2017). Oral tranexamic acid (Lysteda) is not indicated for use in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062678\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic examination (visual acuity, color vision, eye-ground, and visual fields) at baseline and regular intervals during the course of therapy in patients being treated for longer than several days; signs/symptoms of hypersensitivity reactions, seizures, thrombotic events, and ureteral obstruction </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229837\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Forms a reversible complex that displaces plasminogen from fibrin resulting in inhibition of fibrinolysis; it also inhibits the proteolytic activity of plasmin</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">With reduction in plasmin activity, tranexamic acid also reduces activation of complement and consumption of C1 esterase inhibitor (C1-INH), thereby decreasing inflammation associated with hereditary angioedema. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F229852\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 9 to 12 L; CSF levels are 10% of plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~3%, primarily to plasminogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral:  ~45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~2 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 2.5 hours (range: 1 to 5 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (&gt;95% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597778\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The C<sub>max</sub> and AUC values after a single oral dose of 1,300 mg in adolescent females were 20% to 25% less than those in adult females given the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In vitro data suggests that neonates require a lower serum tranexamic acid concentration than adults (6.54 mcg/mL vs 17.5 mcg/mL) to completely prevent fibrinolysis (Yee 2013). In pediatric patients weighing 5 to 40 kg undergoing cardiac surgery with by-pass, a target serum concentration range of 20 to 30 mcg/mL has been used in pharmacokinetic analysis (Dowd 2002; Grassin-Deyle 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12808160\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 5% (50 mg/mL) oral solution may be prepared by diluting 5 mL of 10% (100 mg/mL) tranexamic acid injection with 5 mL sterile water. Label &ldquo;refrigerate&rdquo;. Stable for 5 days refrigerated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 25 mg/mL oral suspension may be prepared with tablets. Place one 500 mg tablet (strength not available in U.S.) into 20 mL water and let stand ~2 to 5 minutes. Begin stirring and continue until the tablet is completely disintegrated, forming a fine particulate suspension (dispersion time for each 500 mg tablet is ~2 to 5 minutes). Administer immediately after preparation.</p>\n    <div class=\"reference\">Lam MS, &quot;Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs,&quot; <i>Pharmacotherapy</i> 2011, 31(2):164-92.<span class=\"pubmed-id\">21275495</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324017\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cyklokapron Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/10 mL (10 mL): $50.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Tranexamic Acid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/10 mL (10 mL): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lysteda Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">650 mg (30): $174.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tranexamic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">650 mg (30): $156.43</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038848\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amchafibrin (ES);</li>\n      <li>Anaxyl (BD);</li>\n      <li>Aneptil (LK);</li>\n      <li>Azeptil (TR);</li>\n      <li>Bionex (BD);</li>\n      <li>Caprilon (FI);</li>\n      <li>Ciclokapron (VE);</li>\n      <li>Cyclokapron (IS, LU, MT);</li>\n      <li>Cyklokapron (AE, AT, AU, BB, BH, CH, CY, DE, DK, EE, EG, ET, FI, GB, IE, IQ, IR, JO, KW, LB, LY, NL, NO, NZ, OM, QA, SA, SE, SG, SY, YE, ZA);</li>\n      <li>Duhemos (VN);</li>\n      <li>Espercil (CL);</li>\n      <li>Exacyl (AE, BE, CZ, FR, HN, LB, LU, PL);</li>\n      <li>Fimoplas (PH);</li>\n      <li>Haemostop (SG);</li>\n      <li>Hemisan (VN);</li>\n      <li>Hemoblock (EC);</li>\n      <li>Hemoclot (PH);</li>\n      <li>Hemostan (PH);</li>\n      <li>Hemotrex (PH);</li>\n      <li>Hexakapron (IL);</li>\n      <li>Kalnex (ID);</li>\n      <li>Lunex (ID);</li>\n      <li>Medsamic (VN);</li>\n      <li>Nexa (ID);</li>\n      <li>Nobleed (LK);</li>\n      <li>Qualixamin (HK);</li>\n      <li>Ranexid (PH);</li>\n      <li>Rikaparin (TW);</li>\n      <li>Ronex (ID);</li>\n      <li>Tiren (MY);</li>\n      <li>Tracid (BD);</li>\n      <li>Tramic (TH);</li>\n      <li>Tranarest (IN);</li>\n      <li>Tranestat (UA);</li>\n      <li>Tranex (BD, IT);</li>\n      <li>Tranexam (RU, TW);</li>\n      <li>Tranexic (TW);</li>\n      <li>Tranexid (ID);</li>\n      <li>Tranlok (LK);</li>\n      <li>Tranmix (VN);</li>\n      <li>Transamin (BR, CN, HK, JP, KR, MY, PE, PK, TH, TW, VN);</li>\n      <li>Transamina (UY);</li>\n      <li>Transic (TH);</li>\n      <li>Tranxa (ID);</li>\n      <li>Trenaksa (UA);</li>\n      <li>Trenaxin (PH);</li>\n      <li>Vydanol (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bowen T, Hebert J, Ritchie B, et al. Management of hereditary angioedema: a Canadian approach.<i> Transfus Apher Sci</i>. 2004;29(3):205-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/14572811 /pubmed\" target=\"_blank\" id=\"14572811 \">14572811 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.<i> Allergy Asthma Clin Immunol</i>. 2010;6(1):24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/20667127 /pubmed\" target=\"_blank\" id=\"20667127 \">20667127 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chauhan S, Bisoi A, Kumar N, et al, &quot;Dose Comparison of Tranexamic Acid in Pediatric Cardiac Surgery,&quot; <i>Asian Cardiovasc Thorac Ann</i>, 2004, 12(2):121-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/15213077 /pubmed\" target=\"_blank\" id=\"15213077 \">15213077 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chauhan S, Das SN, Bisoi A, et al, &quot;Comparison of Epsilon Aminocaproic Acid and Tranexamic Acid in Pediatric Cardiac Surgery,&quot; <i>J Cardiothorac Vasc Anesth</i>, 2004a, 18(2):141-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/15073700/pubmed\" target=\"_blank\" id=\"15073700\">15073700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Craig T, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/23282420 /pubmed\" target=\"_blank\" id=\"23282420 \">23282420 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyklokapron injection (tranexamic acid) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; April 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dadure C, Sauter M, Bringuier S, et al. Intraoperative tranexamic acid reduces blood transfusion in children undergoing craniosynostosis surgery: a randomized double-blind study. <i>Anesthesiology</i>. 2011;114(4):856-861. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/21358317 /pubmed\" target=\"_blank\" id=\"21358317 \">21358317 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. <i>Anesthesiology</i>. 2002;97(2):390-399.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/12151929 /pubmed\" target=\"_blank\" id=\"12151929 \">12151929 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ducloy-Bouthors A, Jude B, Duhamel A, et al, &ldquo;High-Dose Tranexamic Acid Reduces Blood Loss in Postpartum Heamorrhage,&rdquo; <i>Crit Care</i>, 2011, 15(2):R117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/21496253/pubmed\" target=\"_blank\" id=\"21496253\">21496253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eaton MP, &quot;Antifibrinolytic Therapy in Surgery for Congenital Heart Disease,&quot; <i>Anesth Analg</i>, 2008, 106(4):1087-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/18349177/pubmed\" target=\"_blank\" id=\"18349177\">18349177</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farkas H, Varga L, Sz&eacute;plaki G, Visy B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. <i>Pediatrics</i>. 2007;120(3):e713-722. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/17724112 /pubmed\" target=\"_blank\" id=\"17724112 \">17724112 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. <i>Clin Exp Immunol</i>. 2005;139(3):379-394.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/15730382 /pubmed\" target=\"_blank\" id=\"15730382 \">15730382 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goobie SM, Meier PM, Pereira LM, et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. <i>Anesthesiology</i>. 2011;114(4):862-871.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/21364458 /pubmed\" target=\"_blank\" id=\"21364458 \">21364458 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham EM, Atz AM, Gillis J, et al. Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery. J<i> Thorac Cardiovasc Surg</i>. 2012;143(5):1069-1076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/22075061 /pubmed\" target=\"_blank\" id=\"22075061 \">22075061 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grant JA, Howard J, Luntley J, et al, &quot;Perioperative Blood Transfusion Requirements in Pediatric Scoliosis Surgery: The Efficacy of Tranexamic Acid,&quot; <i>J Pediatr Orthop</i>, 2009, 29(3):300-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/19305284/pubmed\" target=\"_blank\" id=\"19305284\">19305284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grassin-Delyle S, Couturier R, Abe E, Alvarez JC, Devillier P, Urien S. A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. <i>Anesthesiology</i>. 2013;118(4):853-862.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/23343649 /pubmed\" target=\"_blank\" id=\"23343649 \">23343649 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gungorduk K, Yildirim G, As&#305;c&#305;o&#287;lu O, et al, &ldquo;Efficacy of Intravenous Tranexamic Acid In Reducing Blood Loss After Elective Cesarean Section: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study,&rdquo; <i>Am J Perinatol</i>, 2011, 28(3):233-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/20979013/pubmed\" target=\"_blank\" id=\"20979013\">20979013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keijzer R, Wilschut DE, Houmes RJ, et al. Congenital diaphragmatic hernia: to repair on or off extracorporeal membrane oxygenation? <i>J Pediatr Surg</i>. 2012;47(4):631-636.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/22498373 /pubmed\" target=\"_blank\" id=\"22498373 \">22498373 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levin E, Wu J, Devine DV, et al, &quot;Hemostatic Parameters and Platelet Activation Marker Expression in Cyanotic and Acyanotic Pediatric Patients Undergoing Cardiac Surgery in the Presence of Tranexamic Acid,&quot; <i>Thromb Haemost</i>, 2000, 83(1):54-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/10669155/pubmed\" target=\"_blank\" id=\"10669155\">10669155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lysteda tablets (tranexamic acid) [prescribing information]. Parsippany NJ: Ferring Pharmaceuticals Inc; October 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murkin JM, Falter F, Granton J, et al, &quot;High-Dose Tranexamic Acid Is Associated With Nonischemic Clinical Seizures in Cardiac Surgical Patients,&quot; <i>Anesth Analg</i>, 2010, 110(2):350-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/19996135/pubmed\" target=\"_blank\" id=\"19996135\">19996135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neilipovitz DT, Murto K, Hall L, et al, &quot;A Randomized Trial of Tranexamic Acid to Reduce Blood Transfusion for Scoliosis Surgery,&quot; <i>Anesth Analg</i>, 2001, 93(1):82-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/11429344/pubmed\" target=\"_blank\" id=\"11429344\">11429344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahmani B, Jahadi HR. Comparison of tranexamic acid and prednisolone in the treatment of traumatic hyphema. A randomized clinical trial. <i>Ophthalmology</i>. 1999;106(2):375-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/9951493 /pubmed\" target=\"_blank\" id=\"9951493 \">9951493 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid RW, Zimmerman AA, Laussen PC, et al, &quot;The Efficacy of Tranexamic Acid Versus Placebo in Decreasing Blood Loss in Pediatric Patients Undergoing Repeat Cardiac Surgery,&quot; <i>Anesth Analg</i>, 1997, 84(5):990-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/9141920/pubmed\" target=\"_blank\" id=\"9141920\">9141920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schindler E, Photiadis J, Sinzobahamvya N, D&ouml;res A, Asfour B, Hraska V. Tranexamic acid: an alternative to aprotinin as antifibrinolytic therapy in pediatric congenital heart surgery. <i>Eur J Cardiothorac Surg</i>. 2011;39(4):495-499. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/20832330 /pubmed\" target=\"_blank\" id=\"20832330 \">20832330 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sethna NF, Zurakowski D, Brustowicz RM, et al, &quot;Tranexamic Acid Reduces Intraoperative Blood Loss in Pediatric Patients Undergoing Scoliosis Surgery,&quot; <i>Anesthesiology</i>, 2005, 102(4):727-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/15791100/pubmed\" target=\"_blank\" id=\"15791100\">15791100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shapiro F, Zurakowski D, and Sethna NF, &quot;Tranexamic Acid Diminishes Intraoperative Blood Loss and Transfusion in Spinal Fusions for Duchenne Muscular Dystrophy Scoliosis,&quot; <i>Spine (Phila Pa 1976)</i>, 2007, 32(20):2278-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/17873823/pubmed\" target=\"_blank\" id=\"17873823\">17873823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tranexamic acid. Trissel&rsquo;s IV-Chek [database online]. Indianapolis, IN: Medi-Span; 2015. http://online.factsandcomparisons.com. Accessed February 11, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Staak FH, de Haan AF, Geven WB, et al, &quot;Surgical Repair of Congenital Diaphragmatic Hernia During Extracorporeal Membrane Oxygenation: Hemorrhagic Complications and the Effect of Tranexamic Acid,&quot; <i>J Pediatr Surg</i>, 1997, 32(4):594-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/9126762/pubmed\" target=\"_blank\" id=\"9126762\">9126762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vangsted P, Nielsen PJ. Tranexamic acid and traumatic hyphaema. A prospective study. <i>Acta Ophthalmol (Copenh)</i>. 1983;61(3):447-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/6353843 /pubmed\" target=\"_blank\" id=\"6353843 \">6353843 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yee BE, Wissler RN, Zanghi CN, Feng C, Eaton MP. The effective concentration of tranexamic acid for inhibition of fibrinolysis in neonatal plasma <i>in vitro</i>. <i>Anesth Analg</i>. 2013;117(4):767-772.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/24023015 /pubmed\" target=\"_blank\" id=\"24023015 \">24023015 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuraw BL. Clinical practice. Hereditary angioedema. <i>N Engl J Med</i>. 2008;359(10):1027-1036.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tranexamic-acid-pediatric-drug-information/abstract-text/18768946 /pubmed\" target=\"_blank\" id=\"18768946 \">18768946 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12854 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F229860\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F229861\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062679\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675770\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062673\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F229847\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F229834\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062683\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F7679527\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062682\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F229906\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F229904\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F229853\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F229838\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300160\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F229842\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F229843\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7679524\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062678\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F229837\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F229852\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597778\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F12808160\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324017\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038848\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12854|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tranexamic-acid-drug-information\" class=\"drug drug_general\">Tranexamic acid: Drug information</a></li><li><a href=\"topic.htm?path=tranexamic-acid-patient-drug-information\" class=\"drug drug_patient\">Tranexamic acid: Patient drug information</a></li></ul></div></div>","javascript":null}